Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease

Overview

Journal Intern Med

Specialty General Medicine

Date 2017 Nov 3

PMID 29093413

Authors

Junichi Iwamoto

Masashi Murakami

Naoki Konishi

Tadakuni Monma

Hajime Ueda

Shoichiro Yara

Takeshi Hirayama

Tadashi Ikegami

Akira Honda

Yasushi Matsuzaki

Affiliations

Soon will be listed here.

Abstract

A 66-year-old Japanese male with a history of Behçet disease exhibited oral and genital ulcers, and a round deep ileocecal ulcer. He was treated with a combination of mesalazine and 20 mg/day of prednisolone (PSL), but was only partially responsive to PSL and we were not able to reduce the steroid dosage. Adalimumab was also administered. However, the ulcer was not completely responsive, and weaning the patient off PSL remained impossible. In contrast, additional treatment with clarithromycin completely healed the refractory active ulcer and left only a scar. Furthermore, the ulcer has since maintained the scar stage despite successfully weaning the patient from PSL.

References

Shinkai M, Henke M, Rubin B . Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008; 117(3):393-405. DOI: 10.1016/j.pharmthera.2007.11.001. View

Inoue S, Nakase H, Matsuura M, Ueno S, Uza N, Kitamura H . Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease. J Gastroenterol Hepatol. 2007; 22(7):984-8. DOI: 10.1111/j.1440-1746.2006.04533.x. View

Jung Y, Hong S, Kim T, Kim W, Cheon J . Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol. 2012; 46(5):e38-45. DOI: 10.1097/MCG.0b013e3182431d56. View

Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B . Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease. Clin Gastroenterol Hepatol. 2014; 13(5):940-8.e3. DOI: 10.1016/j.cgh.2014.08.042. View

Kinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Sasaki T, Kimura H . Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication. Intern Med. 2013; 52(17):1855-62. DOI: 10.2169/internalmedicine.52.0589. View

Sakane T, Takeno M, Suzuki N, Inaba G . Behçet's disease. N Engl J Med. 1999; 341(17):1284-91. DOI: 10.1056/NEJM199910213411707. View

Hisamatsu T, Naganuma M, Matsuoka K, Kanai T . Diagnosis and management of intestinal Behçet's disease. Clin J Gastroenterol. 2014; 7(3):205-12. PMC: 4037558. DOI: 10.1007/s12328-014-0488-0. View

Mochizuki M . Immunotherapy for Behçet's disease. Int Rev Immunol. 1997; 14(1):49-66. DOI: 10.3109/08830189709116844. View

Hakozaki Y, Mitani K, Okada C, Terada H, Kobari S . Effective Treatment of Intestinal Behçet's Disease with Long-Term, Low-Dose Clarithromycin. Case Rep Gastroenterol. 2013; 7(1):122-6. PMC: 3617967. DOI: 10.1159/000350320. View

10.

Morikawa K, Watabe H, Araake M, Morikawa S . Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother. 1996; 40(6):1366-70. PMC: 163332. DOI: 10.1128/AAC.40.6.1366. View

11.

Saadoun D, Wechsler B . Behçet's disease. Orphanet J Rare Dis. 2012; 7:20. PMC: 3472229. DOI: 10.1186/1750-1172-7-20. View

12.

Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K . Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016; 95(24):e3863. PMC: 4998455. DOI: 10.1097/MD.0000000000003863. View

13.

Iida M, Kobayashi H, Matsumoto T, Okada M, Fuchigami T, Yao T . Postoperative recurrence in patients with intestinal Behçet's disease. Dis Colon Rectum. 1994; 37(1):16-21. DOI: 10.1007/BF02047208. View

14.

Krause I, Weinberger A . Behçet's disease. Curr Opin Rheumatol. 2008; 20(1):82-7. DOI: 10.1097/BOR.0b013e3282f154d1. View

15.

Takeshita K, Yamagishi I, Harada M, Otomo S, Nakagawa T, Mizushima Y . Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res. 1989; 15(11-12):527-33. View

16.

Toda K, Shiratori Y, Yasuda M, Enya M, Uematsu T, Shimazaki M . Therapeutic effect of intraarterial prednisolone injection in severe intestinal Behçet's disease. J Gastroenterol. 2002; 37(10):844-8. DOI: 10.1007/s005350200139. View